ACUTE EFFECTS OF OLANZAPINE ON PLASMA LEPTIN, GLUCOSE TOLERANCE FREE FATTY ACIDS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 中心，不一定是研究者的机构。 动物数据表明，奥氮平通过改变瘦素水平诱导体重增加。 本研究的目的是确定奥氮平的急性效应是否会减弱受试者的血浆瘦素并改变其葡萄糖耐量。 本研究将入组约32名年龄18-30岁、BMI 20-25、无精神疾病或慢性疾病的健康志愿者，接受3天10 mg奥氮平或安慰剂治疗，然后在1周后交叉接受相反治疗。 受试者将在GCRC访视前的3天内每天服用一粒药丸。 在此期间，他们将遵循3天300克碳水化合物饮食。受试者将完成他们的饥饿感调查，进行游离脂肪酸、葡萄糖、胰岛素和瘦素的血液测试，然后进行口服葡萄糖耐量测试。 这些相同的程序将在1-2周后重复。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Animal data suggest that olanzapine induces weight gain by alterations in leptin levels. The goal of this study is to determine if the acute effects of olanzapine is to attenuate plasma leptin and alter glucose tolerance in human subjects. This study will enroll approximately 32 healthy volunteers ages 18-30, with BMI 20-25 without psychiatric disorders or chronic disease to receive 3 days of treatment with 10 mg olanzapine or placebo, then crossed over after one week to receive the opposite treatment. Subjects will take one pill daily for the 3 days up to the GCRC visit. During this time they will follow a 3 day 300g carbohydrate diet. Subjects will complete surveys of their hunger, have blood tests for free fatty acids, glucose, insulin and leptin and then undergo the oral glucose tolerance test. These same procedures will be repeated 1-2 weeks later.